Literature DB >> 2797215

Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo.

S B Ross1, D M Jackson.   

Abstract

The kinetic properties of the accumulation of 3H-raclopride, a selective dopamine (DA) D-2 receptor antagonist, in mouse striatum in vivo was examined under various experimental conditions. The accumulation in striatum was saturable in contrast to that in cerebellum, which linearily increased with the dose. The specific binding of 3H-raclopride in the striatum, defined as the difference in the accumulation in striatum and cerebellum 30 min after the injection was completely inhibited by the D-2 receptor antagonists spiperone and (+)-butaclamol [but not (-)-butaclamol] and the DA receptor agonist N-n-propylnorapomorphine. The mean Bmax value of the specific binding was 40.7 +/- 2.8 pmol/g tissue and the mean apparent KD value, based on the dose injected, was 87.8 +/- 11.5 nmol/kg i.v. (18 different experiments). Pretreatment of the mice with a single injection of reserpine 4 h or 3 days beforehand reduced the apparent KD value which in part seemed to be due to the decreased concentration of synaptic DA. Similarly, gamma-butyrolactone injected immediately before raclopride reduced the apparent KD value, whereas amfonelic acid and (-)-amphetamine increased the observed KD values. These findings indicate competition between endogenous DA and raclopride for the D-2 receptors. Both reserpine and gamma-butyrolactone increased the apparent Bmax value by about 50% which indicates a receptor pool of DA for which raclopride does not compete.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2797215     DOI: 10.1007/BF00169199

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  The central stimulatory action of inhibitors of the dopamine uptake.

Authors:  S B Ross
Journal:  Life Sci       Date:  1979-01-08       Impact factor: 5.037

2.  Kinetic properties of the in vivo accumulation of 3H-(-)-N-n-propylnorapomorphine in mouse brain.

Authors:  S B Ross; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

3.  Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.

Authors:  H Hall; L Farde; G Sedvall
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

4.  Effect of gamma-hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum.

Authors:  J R Walters; R H Roth
Journal:  Biochem Pharmacol       Date:  1972-08-01       Impact factor: 5.858

5.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

6.  Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain.

Authors:  C Köhler; H Hall; S O Ogren; L Gawell
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

7.  Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Authors:  S B Ross; D M Jackson; E M Wallis; S R Edwards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

8.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

Authors:  L Farde; H Hall; E Ehrin; G Sedvall
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

Review 9.  Raclopride, a new selective ligand for the dopamine-D2 receptors.

Authors:  H Hall; C Köhler; L Gawell; L Farde; G Sedvall
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1988       Impact factor: 5.067

10.  Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride.

Authors:  C Köhler; A C Radesäter
Journal:  Neurosci Lett       Date:  1986-05-06       Impact factor: 3.046

View more
  16 in total

1.  Kinetic properties of the in vivo accumulation of 3H-(-)-N-n-propylnorapomorphine in mouse brain.

Authors:  S B Ross; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

2.  Difference in in vivo receptor binding between [3H]N-methylspiperone and [3H]raclopride in reserpine-treated mouse brain.

Authors:  O Inoue; K Kobayashi; H Tsukada; T Itoh; B Langstrom
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.

Authors:  D M Jackson; L P Martin; L G Larsson; R F Cox; B L Waszczak; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

4.  NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.

Authors:  H Hall; T Högberg; C Halldin; C Köhler; P Ström; S B Ross; S A Larsson; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Characterization of [3H]nemonapride binding to mouse brain dopamine D2 receptors assessed in vivo and ex vivo for metabolic modeling in PET studies.

Authors:  K Ishiwata; K Inami; T Sasaki; T Nozaki; M Senda
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 6.  The dopaminergic basis of human behaviors: A review of molecular imaging studies.

Authors:  Alice Egerton; Mitul A Mehta; Andrew J Montgomery; Julia M Lappin; Oliver D Howes; Suzanne J Reeves; Vincent J Cunningham; Paul M Grasby
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

7.  Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.

Authors:  S L Dewey; G S Smith; J Logan; J D Brodie; P Simkowitz; R R MacGregor; J S Fowler; N D Volkow; A P Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

8.  Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.

Authors:  R Einstein; N Abdul-Hussein; T W Wong; D H Chang; R Matthews; D P Richardson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

9.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Authors:  M Laruelle; A Abi-Dargham; C H van Dyck; R Gil; C D D'Souza; J Erdos; E McCance; W Rosenblatt; C Fingado; S S Zoghbi; R M Baldwin; J P Seibyl; J H Krystal; D S Charney; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

Authors:  Béla Kiss; István Laszlovszky; Attila Horváth; Zsolt Némethy; Eva Schmidt; Gyula Bugovics; Károly Fazekas; István Gyertyán; Eva Agai-Csongor; György Domány; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-13       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.